Treatment sequences for advanced renal cell carcinoma: A health economic assessment-Reference-Cited by-同舟云学术

Treatment sequences for advanced renal cell carcinoma: A health economic assessment

Published:2019-08-29 Issue:8 Volume:14 Page:e0215761
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Deniz Baris^ORCID,Ambavane Apoorva,Yang Shuo,Altincatal Arman,Doan Justin,Rao Sumati,Michaelson M. Dror

Funder

Bristol-Myers Squibb

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;J Ferlay;Int J Cancer,2015

2. Epidemiology and risk factors for kidney cancer;WH Chow;Nat Rev Urol,2010

3. Howlander N, Noon AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER cancer statistics review, 1975–2013. Available: https://seer.cancer.gov/csr/1975_2013/. Accessed October 15, 2017.

4. Metastatic renal cell cancer;F. Rasmussen;Cancer Imaging,2013

5. Immunotherapy for advanced renal cell cancer;C Coppin;Cochrane Database Syst Rev,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study;Targeted Oncology;2022-06-25

3. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management;Current Treatment Options in Oncology;2022-03-22

4. Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma;European Journal of Cancer Care;2022-03-15

5. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance);Clinical Cancer Research;2021-12-29